targets that were discovered using genetic data, says Harper. "We've become increasingly interested in having more examples of targets discovered or validated by human genetics. "
By becoming part of a much bigger biotech firm, deCODE and its chief executive, Kári Stefánsson, may finally be able to fulfil a promise made throughout the company's 16-year history: to use genetic data to benefit patients. Stefánsson says that deCODE can "contribute to more health benefits faster with a company with a proven track record to make therapeutics".
Stefánsson After the deCODE acquisition, due to be finalized in the next two weeks, Stefánsson will stay on as president of deCODE and become a vice-president at Amgen. He says that deCODE will have no lay-offs and will probably even hire staff. Stefánsson emphasizes that the new ownership will not affect how Icelanders' data are managed. The DNA samples will remain in Iceland and access will be through deCODE, subject to existing privacy-protection policies and oversight by an ethics committee of Icelandic citizens.
Scientists from deCODE are some of the most-cited geneticists, and some researchers worry that as the Icelandic group boosts Amgen's product pipelines, deCODE's leadership in basic research will fade. "deCODE may find it far harder to continue publishing its findings if they're being treated as a potential competitive advantage, " says Daniel MacArthur, a geneticist at Massachusetts General Hospital in Boston.
But Harper dismisses such concerns, saying that it is in Amgen's interest to keep deCODE's scientific edge razor sharp. "For us to in some way squelch that creativity would be very shortsighted. " Stefánsson is confident that business at deCODE will continue as usual. 2012 Amgen announces it will acquire deCODE.
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